ATYR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
-100.0%
190.0K
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
-100.0%
190.0K
0
Operating Expenses
10.9M
-4.9%
11.4M
-22.7%
14.8M
-45.1%
26.9M
+32.6%
20.3M
R&D
6.7M
-7.8%
7.3M
-32.8%
10.9M
-50.8%
22.1M
+43.9%
15.4M
SG&A
4.1M
+0.3%
4.1M
+5.5%
3.9M
-18.7%
4.8M
-2.5%
4.9M
Operating Income
-10881000
+4.9%
-11436000
+22.7%
-14796000
+44.7%
-26745000
-31.7%
-20313000
EBITDA
-10713000
+5.0%
-11274000
+22.9%
-14630000
+45.0%
-26580000
-31.9%
-20147000
Net Income
-10310000
+4.5%
-10792000
+22.7%
-13964000
+45.8%
-25746000
-31.8%
-19532000
EPS (Basic)
$-0.11
+0.0%
$-0.11
+21.4%
$-0.14
+46.2%
$-0.26
-18.2%
$-0.22
EPS (Diluted)
$-0.11
+0.0%
$-0.11
+21.4%
$-0.14
+46.2%
$-0.26
-18.2%
$-0.22
Shares (Diluted)
98.1M
+0.0%
98.0M
-0.1%
98.2M
+1.1%
97.2M
+7.8%
90.1M
aTyr Pharma (ATYR) โ€” Financials